ORCA
Online Research @ Cardiff
Browse by All Cardiff Authors
![[up]](/style/images/multi_up.png)
Up a levelNumber of items: 11.
Mian, Afsar Ali, Haberbosch, Isabella, Khamaisie, Hazem, Agbarya, Abed, Pietsch, Larissa, Eshel, Elizabeh, Najib, Dally, Chiriches, Claudia  ORCID: https://orcid.org/0000-0003-3758-1892, Ottmann, Oliver ORCID: https://orcid.org/0000-0001-9559-1330, Hantschel, Oliver, Biondi, Ricardo M., Ruthardt, Martin ORCID: https://orcid.org/0000-0003-1021-3811 and Mahajna, Jamal
2021.
Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR/ABL1 and its resistance and compound mutants BCR/ABL1T315I and BCR/ABL1T315I-E255K.
Annals of Hematology
100
, pp. 2023-2029.
10.1007/s00277-020-04357-z
|
|
|
|
Mian, Afsar A., Baumann, Ines, Liebermann, Marcus, Grebien, Florian, Superti-Furga, Giulio, Ruthardt, Martin ORCID: https://orcid.org/0000-0003-1021-3811, Ottmann, Oliver G. ORCID: https://orcid.org/0000-0001-9559-1330 and Hantschel, Oliver
2019.
The phosphatase UBASH3B/Sts-1 is a negative regulator of Bcr-Abl kinase activity and leukemogenesis.
Leukemia
33
, pp. 2319-2323.
10.1038/s41375-019-0468-y
|
|
|
Legut, Mateusz, Dolton, Garry, Mian, Afsar, Ottmann, Oliver ORCID: https://orcid.org/0000-0001-9559-1330 and Sewell, Andrew ORCID: https://orcid.org/0000-0003-3194-3135
2018.
CRISPR-mediated TCR replacement generates superior anticancer transgenic T-cells.
Blood
131
(3)
, pp. 311-322.
10.1182/blood-2017-05-787598
|
|
|
|
Haberbosch, Isabella, Rafiei, Anahita, Oancea, Claudia ORCID: https://orcid.org/0000-0003-3758-1892, Ottmann, Oliver ORCID: https://orcid.org/0000-0001-9559-1330, Ruthardt, Martin ORCID: https://orcid.org/0000-0003-1021-3811 and Mian, Afsar
2016.
BCR: a new target in resistance mediated by BCR/ABL-315I?
Genes & Cancer
7
(1-2)
, pp. 36-46.
|
|
|
Oancea, Claudia, Rüster, Brigitte, Brill, Boris, Roos, Jessica, Heinssmann, Maria, Bug, Gesine, Mian, Afsar Ali, Guillen, Nathalie Andrea, Kornblau, Steven M., Henschler, Reinhard and Ruthardt, Martin ORCID: https://orcid.org/0000-0003-1021-3811
2014.
STAT activation status differentiates leukemogenic from non-leukemogenic stem cells in AML and is suppressed by arsenic in t(6;9)-positive AML.
Genes & Cancer
5
(11-12)
, pp. 378-392.
10.18632/genesandcancer.39
|
|
|
|
Khateb, Mamduh, Ruimi, Nili, Khamisie, Hazem, Najajreh, Yousef, Mian, Afsar, Metodieva, Anna, Ruthardt, Martin ORCID: https://orcid.org/0000-0003-1021-3811 and Mahajna, Jamal
2012.
Overcoming Bcr-Abl T315I mutation by combination of GNF-2 and ATP competitors in an Abl-independent mechanism.
BMC Cancer
12
, 563.
10.1186/1471-2407-12-563
|
|
|
|
Mian, Afsar Ali, Metodieva, Anna, Badura, Susanne, Khateb, Mamduh, Ruimi, Nili, Najajreh, Yousef, Ottmann, Oliver Gerhard ORCID: https://orcid.org/0000-0001-9559-1330, Mahajna, Jamal and Ruthardt, Martin ORCID: https://orcid.org/0000-0003-1021-3811
2012.
Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I.
BMC Cancer
12
(411)
10.1186/1471-2407-12-411
|
|
|
|
Mian, Afsar A., Metodieva, Anna, Najajreh, Yousef, Ottmann, Oliver G. ORCID: https://orcid.org/0000-0001-9559-1330, Mahajna, Jamal and Ruthardt, Martin ORCID: https://orcid.org/0000-0003-1021-3811
2012.
p185(BCR/ABL) has a lower sensitivity than p210(BCR/ABL) to the allosteric inhibitor GNF-2 in Philadelphia chromosome-positive acute lymphatic leukemia.
Haematologica
97
(2)
10.3324/haematol.2011.047191
|
|
|
|
Mian, A A, Oancea, C, Zhao, Z, Ottmann, O G ORCID: https://orcid.org/0000-0001-9559-1330 and Ruthardt, M ORCID: https://orcid.org/0000-0003-1021-3811
2009.
Oligomerization inhibition, combined with allosteric inhibition, abrogates the transformation potential of T315I-positive BCR/ABL.
Leukemia
23
, 2242–2247.
10.1038/leu.2009.194
|
|
|
|
Mian, A A, Schüll, M, Zhao, Z, Oancea, C, Hundertmark, A, Beissert, T, Ottmann, O G ORCID: https://orcid.org/0000-0001-9559-1330 and Ruthardt, M ORCID: https://orcid.org/0000-0003-1021-3811
2009.
The gatekeeper mutation T315I confers resistance against small molecules by increasing or restoring the ABL-kinase activity accompanied by aberrant transphosphorylation of endogenous BCR, even in loss-of-function mutants of BCR/ABL.
Leukemia
23
, 1614–1621.
10.1038/leu.2009.69
|
|
|
|
Beissert, Tim, Hundertmark, Alena, Kaburova, Velina, Travaglini, Lorena, Mian, Afsar A., Nervi, Clara and Ruthardt, Martin ORCID: https://orcid.org/0000-0003-1021-3811
2008.
Targeting of the N-terminal coiled coil oligomerization interface by a helix-2 peptide inhibits unmutated and imatinib-resistant BCR/ABL.
International Journal of Cancer
122
(12)
, pp. 2744-2752.
10.1002/ijc.23467
|
|
|